Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer

Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer

header-info

Shlomit Amar-Farkash, PhD, MSc, Anthem Innovation Israel, Tel Aviv, Israel compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with metastatic triple-negative breast cancer in the United States.